Analysts Set Guardant Health, Inc. (NASDAQ:GH) PT at $183.78

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned an average recommendation of “Moderate Buy” from the twenty-five analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, twenty-three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $183.7826.

A number of analysts recently commented on the company. Sanford C. Bernstein lifted their price target on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. Stifel Nicolaus boosted their price objective on Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Citigroup upped their price objective on Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Mizuho raised their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research note on Tuesday, August 25th.

Insider Activity at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 14,180 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares in the company, valued at $472,787. The trade was a 82.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This represents a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 427,024 shares of company stock valued at $67,113,285 in the last 90 days. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Guardant Health

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after buying an additional 25,831 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Guardant Health during the 1st quarter valued at $274,000. Sei Investments Co. lifted its position in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after buying an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after acquiring an additional 54,284 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after acquiring an additional 40,209 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH stock opened at $161.41 on Wednesday. Guardant Health has a 52-week low of $53.40 and a 52-week high of $176.58. The company has a 50-day simple moving average of $159.90 and a two-hundred day simple moving average of $122.74. The company has a market capitalization of $21.66 billion, a price-to-earnings ratio of -46.25 and a beta of 1.57.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. During the same period in the prior year, the business earned ($0.44) EPS. Guardant Health’s quarterly revenue was up 44.3% compared to the same quarter last year. On average, sell-side analysts forecast that Guardant Health will post -2.98 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.